Balanced news tone
News Sentiment
TVRD sentiment intelligence
Tvardi Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
43 relevant articles
Price is moving more forcefully than the current news tone suggests.
77/100 classification confidence.
directly relevant articles
high-authority source matches
+62.4% over one week, +24.2% over four weeks, trend inactive, and below fair value.
Tvardi Therapeutics Company Profile & Introduction
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
77/100 classification
One-week reaction
62.4%
Price confirming higher
Trend fit
Trend inactive
24.2% over four weeks
Fair value
-85.7%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
34
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Fierce Biotech
Direct company coverage
Tvardi's STAT3 inhibitor flunks phase 2 IPF trial amid high dropout rates
Tvardi Therapeutics' STAT3 inhibitor, TTI-101, failed its phase 2 trial for idiopathic pulmonary fibrosis (IPF), showing placebo-like efficacy and high dropout rates primarily due to gastrointestinal adverse events. The company reported that lung function declined in patients rec
- Tone
- Neutral 50/100
- Event
- Macro sensitivity
- Published
- 13 Oct 2025 09:25
- Source
- Fierce Biotech
IndexBox
Direct company coverage
Tvardi Therapeutics: Innovative Approaches to Fibrosis and Cancer - News and Statistics
Tvardi Therapeutics is gaining attention in the biotech sector, with its stock up 32% this year due to its innovative approach to treating fibrosis and cancer. The company focuses on developing oral small-molecule drugs targeting the STAT3 protein, with its lead candidate, TTI-10
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 18 Jul 2025 17:08
- Source
- IndexBox
MarketBeat
Direct company coverage
Tvardi Therapeutics (TVRD) Stock Price, News & Analysis $TVRD
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 May 2025 10:06
- Source
- MarketBeat
FinancialContent
Direct company coverage
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
Tvardi Therapeutics announced its Q1 2025 financial results and business updates, including the completion of its merger with Cara Therapeutics, which boosted its cash reserves. The company is well-financed into the second half of 2026 and expects multiple Phase 2 data readouts f
- Tone
- Positive 73/100
- Event
- Deals and strategy
- Published
- 13 May 2025 16:05
- Source
- FinancialContent
GlobeNewswire
Direct company coverage
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
Tvardi Therapeutics has announced the completion of its merger with Cara Therapeutics, creating a Nasdaq-listed biopharmaceutical company. The combined entity, operating as Tvardi Therapeutics (NASDAQ: TVRD), will focus on developing treatments targeting STAT3 for fibrosis-driven
- Tone
- Positive 72/100
- Event
- Deals and strategy
- Published
- 15 Apr 2025 16:05
- Source
- GlobeNewswire
Investing.com South Africa
Direct company coverage
Cara Therapeutics announces 1-for-3 reverse stock split By Investing.com
Cara Therapeutics, nearing its merger with Tvardi Therapeutics and rebranding as Tvardi Therapeutics, Inc., has announced a 1-for-3 reverse stock split of its common stock. This move, approved by its board and stockholders, will take effect soon, reducing the number of outstandin
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Apr 2025 17:58
- Source
- Investing.com South Africa
Investing.com South Africa
Direct company coverage
Cara Therapeutics approves merger and stock plans By Investing.com
Cara Therapeutics (NASDAQ: CARA) stockholders have approved a merger with Tvardi Therapeutics, Inc., alongside a reverse stock split, an increase in authorized shares, and new equity incentive and employee stock purchase plans. This strategic move aims to address Cara's financial
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 01 Apr 2025 22:36
- Source
- Investing.com South Africa
FinancialContent
Direct company coverage
Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.
Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., Esq., is investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) with Tvardi Therapeutics, Inc. Cara shareholders are expected to own approximately 17.0% of the comb
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 20 Feb 2025 17:25
- Source
- FinancialContent
Quiver Quantitative
Direct company coverage
Cara Therapeutics Announces 1-for-12 Reverse Stock Split and Reduction in Authorized Shares
Cara Therapeutics, Inc. has announced a 1-for-12 reverse stock split of its outstanding shares, effective December 30, 2024, at 5:00 p.m. ET, and a reduction in authorized shares from 200 million to approximately 16.67 million. This move is intended to help the company regain com
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Dec 2024 12:10
- Source
- Quiver Quantitative
CTPost
Direct company coverage
Cara Therapeutics accepts buyout from Houston's Tvardi Therapeutics, ending 20-year run in Connecticut
Cara Therapeutics, a Connecticut-based company, has accepted a buyout offer from Houston's Tvardi Therapeutics, concluding its 20-year history in the state. This acquisition follows Cara Therapeutics laying off most of its employees and receiving FDA
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Dec 2024 22:11
- Source
- CTPost
GlobeNewswire
Direct company coverage
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
Cara Therapeutics and Tvardi Therapeutics have announced a definitive merger agreement to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on fibrosis-driven diseases. The combined entity, expected to operate as Tvardi Therapeutics, will leverage Tvardi's
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Dec 2024 08:09
- Source
- GlobeNewswire
citybiz
Direct company coverage
Cara Therapeutics and Tvardi Therapeutics To Merge
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Dec 2024 08:00
- Source
- citybiz
Simply Wall Street
Direct company coverage
Institutional owners may consider drastic measures as Cara Therapeutics, Inc.'s (NASDAQ:CARA) recent US$29m drop adds to long-term losses
Institutional investors, primarily BlackRock and CSL Limited, own 65% of Cara Therapeutics, Inc. (NASDAQ:CARA), indicating significant influence. A recent US$29 million drop and a 68% one-year loss for shareholders suggest these institutions might take drastic measures, such as s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2023 10:35
- Source
- Simply Wall Street